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Human data and murine studies demonstrate that biological sex and age impact 
inactivated influenza vaccine (IIV)-induced immunity, wherein the antibodies are 
directed towards Influenza virus glycoprotein hemagglutinin (HA) head. Post IIV in 
mice, females of reproductive age generated greater antibody responses leading to better 
protection than males. Whereas, in aged mice, where the immunity is waning, the sex-
differences are lost and are associated with reduced concentrations of sex-steroids. 
Whether universal influenza vaccines (UIV) producing antibodies towards the highly 
conserved stalk region of HA protein are also influenced by biological sex and age has 
not been studied. We hypothesized that age-associated sex differences to influenza 
vaccine response will be observed regardless of target region of antibodies.  
METHODS: 
We used the chimeric hemagglutinin (cHA)-based UIV, which produces antibodies 
towards the stalk region of the HA protein. We vaccinated adults and aged C57BL6 mice 
using a prime-boost-boost strategy with a live-attenuated influenza B virus containing 
chimeric H9/1, recombinant H11/1 and H12/1 protein, respectively. We evaluated the 
antibody responses of stalk-specific IgG, IgG isotypes and avidity against H1 stalk and 
cross-reactive IgG response against H9N2, H6N3, H5N1 and H3N2 viruses. We 
challenged the mice with H1N1 virus to monitor vaccine-induced protection. We also 
passively transferred antibodies from adults to their sex-matched aged counterparts to 






Post-vaccination antibody analysis demonstrated that adult mice developed higher 
quantity and quality of antibody than aged mice. Adult mice had greater stalk-specific 
IgG titers against multiple subtypes of group 1 influenza A viruses and had greater 
antibody avidity, regardless of sex. The age-associated decline in immunity was sex-
specific, where aging significantly reduced antibody responses in female but not male 
mice. Post-challenge with H1N1 virus, aged females suffered greater morbidity and had 
higher viral titers than age-matched males and younger females. Passive transfer of serum 
from sex-matched adult mice to aged mice was not sufficient to protect aged mice from 
severe outcomes following infection.  
CONCLUSION: 
In conclusion, these findings suggest a fundamental difference between males and 
females during aging. Hence biological sex and age should be considered in preclinical 
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Influenza virus biology: 
Influenza viruses (family Orthomyxoviridae) are segmented, negative-strand RNA 
viruses requiring an RNA dependent RNA polymerase of viral origin in order to replicate 
inside the host cell (Bouvier & Palese, 2018). There are three genera of the virus, 
influenza A, B, and C, identified and known to infect humans. In 2011, a novel influenza 
virus was identified which was named in 2016 as influenza D virus by the International 
Committee of Taxonomy of Virus (Ferguson et al., 2016), due to its genetic distinction 
and inability to reassort with influenza C virus (Su et al., 2017). Since it is a negative 
sense virus, the RNA in its crude form is not infectious and must be converted to 
positive-sense RNA in order to be translated (Bouvier & Palese, 2018). The influenza A 
and B viruses each comprise of eight segments of these negative sense, single-stranded 
viral RNA. Nomenclature of these viruses, mainly influenza A viruses (IAVs) is based on 
the subtype of the virus surface glycoproteins, hemagglutinin (HA) and neuraminidase 
(NA). Gene segments 4 and 6, respectively, code for HA and NA genes (Bouvier & 
Palese, 2018).  
Influenza viruses recognize N acetylneuraminic (sialic) acid residues on the host 
cell surface. The carbon 2 of sialic acid can bond with either carbon 3 or carbon 6 of 
galactose, leading to the formation of alpha 2,3 or alpha 2,6 linkages. These sialic acid 
moieties are recognized by HA spikes present on the virus. Human influenza viruses can 
attach to the 2,6 alpha sialic acid residues present in the upper respiratory epithelial cells 




epithelium of aquatic birds.  The 2,3 sialic residues however are also present in the lower 
respiratory region, mainly on alveolar cells. What makes influenza a respiratory human 
pathogen is the presence of alpha 2,6 sialic acid residues on the human tracheal epithelial 
cells (Davis, 2014). The 2,3 sialic acid residues are mainly present in the gut epithelium 
of aquatic birds, making them a reservoir of these viruses (Medina & García-Sastre, 
2011). One of the factors for transmission of avian influenza viruses in humans, as 
recently observed for H5N1 in 2019 in Nepal (WHO: Information on Avian Influenza A 
(H5N1) Identified in Human in Nepal), is the presence of these 2,3 sialic acid residues in 
the lower respiratory epithelium of humans, although in less abundance. Attachment of 
these exotic influenza viruses to the receptors in humans and subsequent multiplication 
can cause severe damage due to not having encountered the virus before thereby having 
no adequate preexisting immunity. The HA region of the virus contains sialic acid 
receptor binding sites. When the virus replicates, this HA is cleaved by serine proteases 
into HA1 and HA2, where HA2 mediates the fusion of the virus with the cell membrane. 
Following the attachment, the virus is endocytosed, and in presence of low pH, two 
events are observed, first is a conformational change in the HA which exposes its fusion 
peptide leading to merger of the viral envelope with the endosome membrane. This leads 
to release of the viral ribonuclear proteins (RNPs) into the cytoplasm (Bouvier & Palese, 
2018). Second is the pumping up of hydrogen ions (H+) from the acidic endosomal 
environment into the virus through membrane protein 2 (M2) ion channel, which disrupts 
all the protein-protein interaction allowing RNPs to be released into the cytoplasmic 
environment. Once released into the cytoplasmic environment, these RNPs travel to the 




synthesis occurs for both the viral RNAs and the mRNA for protein synthesis (Fukuyama 
& Kawaoka, 2011).  
Of the three genera infecting humans, Influenza A viruses (IAVs) cause most 
seasonal infections and cause all pandemics, to date. The primary natural host species of 
IAVs include wild aquatic waterfowl and shorebirds (Webster et al., 1992), but cross-
species transmission can occur which leads to sustained influenza outbreaks in poultry 
and mammals, such as humans, pigs, horses, seals and mink (Parrish, Murcia, & Holmes, 
2015). Influenza viruses are predominantly respiratory pathogen in humans. They 
replicate in both the upper respiratory and lower respiratory tract and the replication 
peaks approximately 48 hours post-inoculation into the nasopharynx and decreases 
gradually (Taubenberger & Morens, 2008).  
Influenza pathogenesis and epidemiology: 
Influenza is an acute respiratory disease in humans identified with the onset of 
high fever, coryza, cough, headache, prostration, malaise, and inflammation of the upper 
respiratory system (Su et al., 2017). Influenza affects people of all ages, but the 
prevalence is observed highest in school-age children. The severity of the disease varies 
within the age, with infants, aged population and people with underlying illnesses 
suffering the most. Infection with IAVs in people with diabetes mellitus, chronic 
pulmonary, or cardiac diseases leads to a high risk of progressing to severe 
complications, including pneumonia, bronchitis and death in some cases (Taubenberger 




The major reason why influenza is an annual threat, an economic burden, and 
needs millions of dollars to be invested in vaccine production is due to a phenomenon 
called antigenic drift observed in the virus. Antigenic drift refers to a mechanism through 
which variations are observed in the seasonal influenza viruses in the antibody binding 
sites to avoid neutralization by the immune response (Chen & Deng, 2009). The mutation 
rate of HA and NA of Influenza A is estimated to be at 6.7 * 10-3 nucleotide substitution 
(Lofgren et al., 2007). These mutations essentially make the antibodies generated against 
the prior season’s viruses ineffective, rendering an advantage to the virus to spread and 
infect.  
Influenza A viruses have been associated with causing multiple pandemics over 
the last century, killing millions of people around the world (Kilbourne, 2006), with 
pandemic IAVs caused by an antigenic shift in the circulating virus (Manley, 2013). 
Antigenic shift refers to the evolution of novel strains of influenza through reassortment 
of its gene segments with an exotic influenza virus such as an avian or zoonotic influenza 
virus. Zoonotic infections, in some cases, such as Ebola and Hantavirus infections, may 
be sporadic and severely pathogenic, rendering humans as a dead-end host. Whereas, 
some infections with a zoonotic pathogen can lead to it becoming stable for replication 
and transmission in the human population, such as observed in HIV and SARS (Manley, 
2013). In the case of the influenza 2009 H1N1 pandemic, the virus had partial elements 
from the human virus and partial from a zoonotic influenza virus and was able to 
replicate and transmit disease in the human population (Christman et al., 2011). Since the 
zoonotic elements of the virus have been “unseen” by the human immune system, they 




In the US, the Centers for Disease Control and Prevention (CDC) has estimated 
around 9.3 to 49 million influenza-related illnesses, around 140,000 to 960,000 
hospitalizations, and around 12,000 to 79,000 deaths annually in the US alone (CDC: 
Estimated Influenza Illnesses, 2017). According to the World Health Organization 
(WHO), the seasonal influenza epidemics result in 3 to 5 million cases of severe illnesses 
and around 290,000 to 650,000 respiratory deaths, mainly affecting aged population 
(>=65 years of age) in industrialized countries (WHO: Seasonal Influenza, 2014). The 
exact statistics and extent of seasonal influenza are not known in developing countries 
but is expected to affect children under five years of age the most (Lafond et al., 2016). 
IAVs have also been associated with causing multiple pandemics over the last century, 
killing millions of people around the world (Kilbourne, 2006). Such pandemics occurred 
during the years 1918, 1957, 1968 and 2009 (Figure 1) (Christman et al., 2011). 
Antigenic drifts of influenza viruses are responsible for the seasonal influenza epidemics, 
while the antigenic shift is responsible for pandemics.  
  




Influenza control measures: vaccination and prevention  
The best way to prevent the spread of influenza viruses is through vaccinations 
(WHO, 2014). In children, the Inactivated influenza vaccine (IIV) is an efficient and cost-
effective intervention, despite some of its limitations (Salleras et al., 2013). The CDC 
estimated that influenza vaccines prevented 7 million influenza illnesses, around 100,000 
hospitalizations, and 8000 deaths in the 2018-2019 season (CDC 2018). The majority of 
deaths averted by influenza vaccines in the previous decade were in aged people and 
children younger than five years of age (Foppa et al., 2015). The currently available 
seasonal vaccines, however, must be reformulated every year, depending on the 
circulating influenza strain. Thus, the effectiveness of these vaccines depends on if the 
circulating strains match the selected vaccine strains. Reformulation takes place twice 
each year for the northern and southern hemisphere and 7-8 months before the influenza 
season selection of vaccine strains is finalized to begin the vaccine production (Houser 
and Subbarao, 2015).  
There are currently three types of vaccines for influenza that are licensed and 
available in the US: 1) the inactivated influenza vaccine, 2) live attenuated influenza 
vaccines, and 3) recombinant influenza vaccines (Houser and Subbarao, 2015). All the 
three licensed vaccines are multivalent and comprise components of both influenza A and 
B viruses. 
The inactivated influenza vaccines (IIVs) are available as trivalent (TIV), 
composed of two subtypes of Influenza A (H1N1 and H3N2) and one strain of Influenza 
B virus or as quadrivalent (QIV), having two subtypes of influenza A virus and two 




inactivated vaccines such as Fluarix, FluLaval, Flucelvax are quadrivalent, and Afluria 
and Fluzone are trivalent vaccines. These are split virion/subunit vaccines that contain 15 
μg of the purified HA protein, unadjuvanted, from egg grown virus, delivered 
intramuscularly (CDC, 2018). 
Twice every year, the WHO consults with its collaborating centers for reference 
and research on circulating influenza virus strains and makes recommendations on the 
composition of the year’s influenza vaccine, based on the surveillance and laboratory 
data (Stöhr, Bucher, Colgate, & Wood, 2012). The seasonal IIVs are also available as 
both high dose and adjuvanted vaccines for aged individuals and have shown to increase 
the antibody response and decrease influenza-related illnesses in this population 
(DiazGranados et al., 2014). The high dose vaccine contains four times the amount of 
antigen as a regular influenza shot and the adjuvanted influenza vaccine, commercially 
available as Fluad, contains the MF59 adjuvant, which has shown to stimulate CD4 
memory T cell response (Falsey et al., 2009). 
The live-attenuated influenza virus (LAIV) vaccines are comprised of the same 
influenza strains present in the QIV but as a live virus delivered intranasally. The live 
virus has specific mutations which make it temperature-sensitive and hence can replicate 
in the cooler temperature of the nasal cavity, as opposed to the higher temperature of the 
lower respiratory tract, restricting its replication there (Houser and Subbarao, 2015). 
LAIV results in the production of strain-specific IgG responses, as observed in response 
to IIV, but also stimulates mucosal IgA and T cell responses. LAIV is also effective in 
protecting and generating a response against some strains of antigenically drifted 




the Advisory Committee on Immunization Practices (ACIP) voted on discontinuation of 
the LAIV for the 2016-2017 season. The preliminary data of LAIV effectiveness in 
children between 2 to 17 years of age showed exceptionally low effectiveness of 3% as 
compared to 63% effectiveness in its alternative method, IIV (CDC, 2017)  
The third type of influenza vaccine is a recombinant HA protein vaccine, 
commercially available as FluBlok. This recombinant HA protein vaccine is produced in 
a baculovirus vector expressing the HA protein. Despite the limitation of its short shelf 
life, it is recommended for vaccinating adults above 18 years of age and is ideal for 
people with egg allergy (Houser and Subbarao, 2015). FluBlok contains three times the 
amount of HA present in TIV and has shown to induce a higher HAI antibody response 
compared to TIV. Hence it can be a good option for populations at risk for influenza (M. 
M. J. Cox, Patriarca, & Treanor, 2008).  
Anti-viral treatments: 
Vaccinations are currently the best way to minimize the risk and transmission of 
influenza. Apart from those, there are anti-viral treatments available as recommendations 
for patients with confirmed cases of influenza who are hospitalized, have a severe or 
progressive illness or are at a high risk of influenza complications such as children under 
the age of 2 years, older individuals, people with co-morbidities and pregnant females. 
There are multiple drugs available targeting different influenza virus proteins. 
Neuraminidase Inhibitors, endonuclease inhibitors and drugs targeting the M2 ion 




Limitations of current seasonal influenza virus vaccines: 
Dependence on embryonated eggs: The dependence of vaccines on production in 
chicken eggs results in the insertion of egg-adaptation mutations that are not present in 
circulating strains (Yang et al., 2019). Also, production takes an extended period, which 
can cause delays or limits in available doses if some selected viruses do not grow well in 
chicken eggs (Rajaram et al., 2020). In the case of a pandemic, when the demand is 
immediate and higher, the use of egg for vaccine production would be an obstacle, 
especially if the pathogen infects poultry (Houser and Subbarao, 2015) (Hannoun, 2013). 
Lengthy timeline for vaccine production: Vaccine production for influenza 
includes multiple steps, the majority of which have to be done before the influenza 
season. This includes starting from evaluating the surveillance data, selecting the vaccine 
strains, virus amplification, vaccine preparation to the packaging of the vaccine. This 
process takes a lot of time and effort, like every other vaccine, but especially becomes a 
prolonged economic burden when it must be repeated annually (Smith et al., 2014). 
Annual vaccination: The major limitation to influenza vaccines is the annual need 
for vaccination observed due to a decline in vaccine-specific antibodies along with the 
annual variation in the virus surface glycoprotein. Several researchers are working on 
developing vaccines targeting the conserved HA stalk region, M2 ion channel and NP 
protein (Krammer & Palese, 2013).  Most of the vaccines against other infectious 
diseases are required or recommended once or twice in a lifetime, whereas vaccination 
against influenza becomes a burden due to its annual need. The seasonal vaccine 
coverage for influenza during the 2018-2019 season was seen to be less than 50% in 




peoples’ lack of interest in annual vaccination (CDC: Early-Season Flu Vaccination 
Coverage–United States, November 2018). United States is one of the countries that have 
achieved the WHO’s recommended goal of increasing influenza vaccine coverage up to 
50% by 2006 for individuals aged 65 years and older, which have coverage of 71.5% as 
of 2017. This has not, however, resulted in a corresponding decrease in the morbidity and 
mortality in this aged population, indicating the incompetency of the available vaccines 
in the elderly population, which comprise of almost 15% of the total US population 
(United States Census Bureau, 2019). 
Ineffective against novel strains: The current influenza vaccines are enough for 
protection against seasonal circulating strains but are essentially ineffective against a 
novel strain of influenza virus. With the close contact of humans with poultry and 
animals, such as pigs, the potential for recombination of zoonotic influenza with human 
influenza becomes higher, as previously observed in the multiple pandemics 
(Taubenberger & Kash, 2010). Both IIVs and LAIVs have been tested as potential 
vaccine candidates for influenza pandemics and shown to display low immunogenicity 
and need for multiple vaccinations (Baz & Luke, 2013). A better solution would be an 
influenza vaccine targeting the conserved sites of influenza viral proteins and providing 
long-term protection against multiple influenza subtypes. 
Immunosenescence in the elderly: Influenza most severely affects the aged 
population, i.e., individuals above 65 years of age, due to progressive decline in immune 
response observed in this population, termed as immunosenescence (Aw, Silva, & 
Palmer, 2007). Even in the circumstances of the vaccine strain matching the circulating 




ranges from 17 to 51% in individuals over 65 years of age and further declines in those 
over 70 (Goodwin, Viboud, & Simonsen, 2006). The efficacy of the IIVs is seen to be 
waning in elder individuals. Immunization leads to the production of vaccine-specific B 
cells, which differentiate into vaccine-specific plasmablasts in the germinal centers 
(GCs), and by 6-8 days, they leave the GCs and enter the blood circulation. ELISPOT 
analysis of vaccine-specific plasmablasts at 7 days post-vaccination revealed a decrease 
in their number and the concentration of Plasmablast-derived polyclonal antibodies 
(PPAbs) in the elderly as compared to the young adults (R. J. Cox et al., 1994) (Sasaki et 
al., 2011). A recent meta-analysis study comparing the relative vaccine efficacy of high 
dose inactivated trivalent influenza vaccine (HD-IIV3), and standard-dose inactivated 
trivalent influenza vaccine (SD-IIV3) demonstrated that HD-IIV3 exhibited better 
protection against influenza-like illnesses than SD-IIV3 with a relative vaccine efficacy 
of 19.5% (Fisman, Agrawal, & Leder, 2002). The current seasonal influenza vaccines 
have a higher dose recommended for the elderly to enhance the immunogenicity of the 
vaccines in this population. The specific chain of mechanisms governing this lower 
efficacy of IVs in the elderly population is, however, still under investigation. 
Absence of an accurate correlate of protection: The hemagglutinin inhibition 
(HAI) assay is presently considered as the standard measure of antibody titer induced by 
vaccination and is accepted as the correlate of protection against influenza (Houser and 
Subbarao, 2015). A titer of 1:40 is the threshold, beyond which approximately 50% of the 
population is considered protected from influenza infection.  However, this assay does 
not consider the T cell response generated by the body after vaccination and there is poor 




The HAI titer threshold for protection is not consistent for all age groups as well. 
(Weiskopf, Weinberger, & Grubeck-Loebenstein, 2009) (Davies & Grilli, 1989) 
Universal influenza vaccines:  
As per the limitations discussed above, there is a need for an improved influenza 
vaccine, including the consideration of universal influenza vaccines. “Universal”, as 
such, is a misleading term, but the National Institute of Health (NIH) has some guidelines 
for a vaccine to be considered as a universal influenza vaccine. It includes that the 
vaccine should be protective for more than a year, should protect against group 1 and 
group 2 influenza viruses, should be at least 75% effective, and must be safe for all age 
groups (NIH: Universal Influenza Vaccine Research). In the case of seasonal IIVs, the 
major antibody target is the immunodominant HA head. This head region is highly 
mutating, making the current season’s vaccine ineffective next season (Houser and 
Subbarao, 2015). The membrane-proximal stalk region of the HA is an immune-
subdominant, highly conserved region. It has been challenging to develop a vaccine 
against the conserved stalk region due to its immune-subdominant nature and the fragile 
nature of its epitopes (Krammer & Palese, 2013). 
  
Figure 2: Ribbon diagram and schematic representation of the influenza HA protein (Y. 




The predominant immune response generated in response to current influenza 
vaccines is the neutralizing antibody response (humoral) against the HA protein head. 
Contrarily, the universal influenza vaccines currently in development are focusing on 
generating a broader immune response comprised of humoral, cellular, and innate 
responses (Sasaki et al., 2008). Currently, there are several universal influenza vaccine 
platforms in development. The principal targets for universal influenza vaccine 
development include the HA stalk region, headless HAs, nucleoprotein (NP), and M2 ion 
channel protein (Rao et al., 2010). NP protein is involved in encapsidation of the viral 
genome, which forms a ribonucleoprotein particle for transcription and packaging. NP 
also interacts with other influenza viral proteins, such as PB1, PB2, M1 and cellular 
proteins such as F-actin for transcription control (Portela & Digard, 2002). The M2 
protein, on the other hand, is involved in protein translocation and is also the primary 
target for influenza prophylactic drugs such as amantadine and rimantadine (Pielak & 
Chou, 2011). The NP protein and M2 ion channel protein have an essential task in virus 
pathogenesis and are being researched in animal models as a potential universal influenza 
vaccine candidate for clinical trials (Y. H. Jang & Seong, 2019). 
The other two significant approaches to induce a broadly neutralizing antibody 
response are constructing headless HAs, chimeric HA protein, or mosaic HA protein 
platform(Krammer & Palese, 2019). The first headless HA constructs were developed in 
the 1980s, by treating the virus with acid to unmask the HA stalk and with a reducing 
agent to remove the HA head region (Graves, Schulman, Young, & Palese, 1983). This 
treatment, however, destroyed the conformational epitopes of the virus. Recently, 




stalk reactive antibodies in mouse models, and further investigation on its efficacy is 
under investigation (Yassine et al., 2015). 
The chimeric hemagglutinin(cHA) based universal influenza vaccine approach combines 
two elements: 1) Use of chimeric HAs and 2) sequential vaccination. A chimeric 
hemagglutinin is a recombinant HA protein that combines the use of HA stalk domain 
from a human influenza virus with “exotic” globular head domains derived from another 
influenza A virus subtypes (Hai et al., 2012). By repeatedly vaccinating mice with 
chimeric HAs containing the same stalk and a different head construct for each 
vaccination leads to the production of enhanced stalk directed response. These stalk 
specific antibodies are found to be broadly neutralizing and protective against infection 
with pandemic H1N1, H5N1, and H6N1 viruses in the mouse model (Krammer et al., 
2013).  
Recently published interim results of the randomized, placebo-controlled, phase 1 clinical 
trial of the chimeric hemagglutinin universal influenza vaccine assessed the efficacy of 
three regimens: 1) chimeric H8/1 (H8 head/H1 stalk) hemagglutinin-based live-
attenuated vaccine followed by the boost with a non-adjuvanted chimeric H5/1 
hemagglutinin-based inactivated vaccine; 2) chimeric H8/1 hemagglutinin-based live 
attenuated vaccine followed by a boost with an ASO3-adjuvanted chimeric H5/1 
hemagglutinin-based inactivated vaccine and; 3) an ASO3-adjuvanted cH8/1 IIV prime 
followed by an ASO3 adjuvanted cH5/1 IIV boost. They demonstrated that the 
inactivated regimens induced a sufficient anti-HA stalk antibody response post boost 
against H2, H9 and H18 recombinant hemagglutinins, pandemic H1N1, and avian-swine 




second boost, questioning the potential of this vaccine platform as a truly universal 
influenza vaccine. However, the production of cross-reactive antibodies and lack of 
safety concerns make it a good candidate for a pandemic vaccine, which can be delivered 
in cases of future unexpected pandemics (Bernstein et al., 2020).  
Host factors affecting vaccine efficacy:  
 Variations in immune responses to vaccinations have been observed at the 
population as well as individual level, linked to several cofactors harbored by the 
vaccinees. In an HIV g120 vaccine clinical trial, race/ethnicity was observed to influence 
the geometric mean titers of neutralizing antibody responses, with African American 
participants having 2.6-4.7 times higher GMTs than white participants (Montefiori et al., 
2004). Genetic factors such as the highly polymorphic Human Leucocyte Antigen (HLA) 
system involved in antigen presentation and less polymorphic pathway of Toll-like 
receptors involved in antigen recognition are involved in varying immune responses 
observed to vaccinations (Kimman, Vandebriel, and Hoebee, 2007).  Coexisting 
conditions and infections impact immune responses to vaccines as well. Underlying 
helminth infections among cholera patients demonstrated reduced mucosal immune 
responses to an immunodominant cholera antigen, Cholera toxin B (CTB), a component 
of an internationally licensed oral cholera vaccine, Dukoral (Baldauf et al., 2015). Aging 
also has a notable impact on the outcome, susceptibility, spread of infections, and 
correspondingly also impacts one of the infectious disease prevention strategies, 
vaccinations. The seasonal influenza vaccine efficacy is lower in the elderly population 
(i.e., individuals 65 years and older) than younger adults, with the elderly population 




85% seasonal influenza-related deaths (Wilhelm, 2018). Hepatitis B vaccine has been 
linked with eliciting a varying degree of response amongst different age groups, with an 
elevated risk of nonresponse to Hep B vaccines in older individuals (Fisman et al., 2002). 
In a Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the 
efficacy of the pneumococcal conjugate vaccine, PCV13, in preventing vaccine-type 
community-acquired pneumonia (VT-CAP) and vaccine-type invasive pneumococcal 
disease (VT-IPD), was shown to decline with increasing age (Van Werkhoven et al., 
2015).  
One of the factors leading to this trend is “Immunosenescence”. 
Immunosenescence is the age-associated progressive decline in immune response which 
is characterized with a decline in several lymphoid-biased hematopoietic stem cells, naïve 
B and T cells, impaired B cell function, thymic involution and many more changes 
leading to decline of a robust immune response(Simon, Hollander, & McMichael, 2015). 
These molecular and cellular changes affect the response expected to vaccines and will 
be discussed further in detail in the context of influenza vaccines in upcoming sections. 
Biological sex and gender have also been associated with affecting the influenza 
virus vaccine acceptance, responses, and overall efficacy (Flanagan et al., 2017). 
Biological sex, which is defined based on the anatomy of an individual’s reproductive 
organs, secondary sex characteristics, sex-specific hormones, and sex chromosome 
complement, can affect immunological responses to vaccines (Flanagan et al., 2017). 
There is a female-biased immune response observed after vaccination with influenza, 
Hepatitis B, Herpes virus and small-pox vaccine (Taneja, 2018). The primary correlate of 




has been observed to be higher in females than males post-vaccination in case of seasonal 
IIVs, yellow fever vaccine, rubella, measles and mumps vaccine, rabies vaccine and 
dengue vaccines (Klein, Jedlicka, & Pekosz, 2010). Aged males are shown to generate a 
higher antibody titer to the Td/Tdap vaccine (Bayas et al., 2001). Apart from the impact 
of biological sex on vaccines, there is also a visible impact gender creates on the rate of 
acceptance of vaccines, uptake of vaccines and reporting of adverse conditions to 
vaccinations, where females have shown to report more adverse reactions to vaccines 
than males (Eilers, Krabbe, & de Melker, 2014). Overall, the nonconformity in vaccine 
efficacy amongst different sexes and genders calls for a need to consider this host factor 
as an important element in vaccine clinical trials and hence requires more in-depth 
research dictating the mechanisms of variance. 
Of the multiple factors impacting the vaccine efficacy, this project approached the 
evaluation of influenza vaccine efficacy specifically through an outlook of biological sex 
and age. 
 
Impact of biological sex on influenza vaccine-induced immunity  
 Both the biological sex and gender, as mentioned earlier, has shown to impact the 
comprehensive response to infections and vaccinations. In the case of influenza 
infections, WHO has reported the worse outcome of pandemic influenza and avian H5N1 
infections to appear in young adult females, pressing the need for considering sex and 
gender as an essential issue while evaluating outcomes of a disease in a population. The 




young adult females (Sex, gender and influenza - World Health Organization). Multiple 
hypotheses are highlighting the effect of differences in exposure to the virus through 
behavior or occupation leading to these differences. Nevertheless, biological differences 
in the sexes also contribute to these differences in outcomes and need further 
investigation in understanding the molecular drive for these differences.  
When adult male and female C57BL/6 mice were inoculated with mouse-adapted 
H1N1 (i.e., A/Puerto Rico/8/34) or H3N2 (i.e., A/Hong Kong/68) using 5 log10 dilutions 
to determine the lethal dose 50 (LD50), i.e., the amount of virus required to kill 50% of 
the test population) for each sex, the LD50 for females was seen to be 11-fold lower for 
H1N1 and four-fold lower for H3N2 than the LD50 for males (Lorenzo et al., 2011). 
Various studies have demonstrated the immune response to influenza vaccines, but a few 
studies mention the role played by biological sex and its impact on vaccine efficacy. 
Seasonal IIVs and LAIV have coverage between 40-50% in the adult population in the 
US (CDC US Flu Vaccination Coverage), hence assessing the impact of host factors such 
as the biological sex is vital in evaluating vaccine efficacy.  
In 2018, Fink et al. demonstrated the impact of biological sex, specifically in the 
case of influenza vaccine-induced immunity and the possible mechanisms leading to this 
observation. Their murine studies demonstrated three major results: 1) infection of male 
and female mice intranasally with low dose 2009 H1N1 virus resulted in greater IgG and 
neutralizing antibody responses, along with higher total B cell IgA, greater germinal 
center B cells, larger germinal centers in female mice than the male mice. Females also 
had greater frequencies of  CD8+ T cells, CD8+ central memory cells, and tissue-resident 




which protects through antibody-mediated responses, resulted in higher IgG and 
neutralizing antibody response in female mice along with females showing better virus 
clearance than males, post-challenge with an H1N1 drift variant virus; 3) epigenetic 
control of Tlr7 (which is encoded on the X chromosome) expression in B cells is greater 
in splenic B cells from vaccinated females than males (Fink et al., 2018). Females have 
two X chromosomes in their cells, whereas males contain one X and one Y chromosome. 
In females, one of these X chromosomes is randomly inactivated through X chromosome 
inactivation (XCI) to balance the dosage of gene expression between the females and 
males (Schurz et al., 2019). This X chromosome has both innate and adaptive immune 
system genes, including TLR7 and 8, IRAK1, NF-kB essential modulator (Kawai & 
Akira, 2006)(Bustamante et al., 2011).  
TLR7 is both an X-linked gene and an intracellular receptor that recognizes 
ssRNA and has been shown to successfully escape the X inactivation (Souyris et al., 
2018). TLR7 localizes in the endosomal compartment of the cell and elicits a robust type 
1 interferon response upon sensing ssRNA and is essential for the development of 
germinal centers, somatic hypermutation, and selection of high-affinity B cells (Swiecki 
& Colonna, 2015). Fink et al., revealed that this TLR7 expression was higher in B cells 
isolated from vaccinated female mice as compared to the vaccinated male mice, which 
could explain the better antibody response observed in the female mice (Fink et al., 
2018). Human serological data have demonstrated that young adult females (18-45 years 
old) had higher IL6 response, which is involved in the germinal center formation, 
antibody production and class switching, than the males, post-vaccination with the TIV 





Along with the role of genes, sex hormones have shown to impact the immune 
response as well (Taneja, 2018). The immune cells, such as neutrophils, mast cells, 
macrophages, B cells and T cells, have the androgen or estrogen receptor on its surface 
(Lai et al., 2012). Binding of sex hormones with these receptors leads to downstream 
changes in signaling cascades, which can further regulate the response of those immune 
cells (Fish 2008). Estrogen is known to modulate the B cell response and activate the Th2 
response after encountering a pathogen (CUTOLO et al., 2006). In the case of 
testosterone, this male-specific hormone has shown to activate T cell, precisely CD8 T 
cell response and enhancing Th1 response and production of the anti-inflammatory 
cytokine IL-10 (Taneja, 2018). A recent paper published by Potluri et al., highlights the 
role of sex hormones specifically in influenza vaccine induced immunity. In humans, 
they evaluated the antibody response in adults and aged population post vaccination with 
the monovalent A/Cal/09 H1N1 vaccine. Adult females had a higher neutralizing 
seroconversion rate post-vaccination than the males, but not in the case of the aged 
population, which correlated with higher estradiol concentration in adult females than the 
aged female and higher testosterone concentration in adult male than aged male. Mouse 
studies conducted to confirm the consistency of the results obtained in humans 
demonstrated that the adult female mice had significantly higher neutralizing antibody 
titers at day post-vaccination 35, and higher IgG titers, IgG2c titers at both 28 and 35 
days post-vaccination with the monovalent A/Cal/09 H1N1 vaccine with a prime-boost 




biased immunity observed was no longer detected, confirming the correlation between 
sex hormones and the vaccine response (Potluri et al., 2019). 
Impact of aging on influenza vaccine-induced immunity 
 Aging is accompanied by a decline in physiological functions in the body, 
progressing towards age-associated mortality (Flatt, 2012). Multiple theories such as 
antagonistic pleiotropy theory (AP), mutation accumulation theory, theories involving a 
reduction in the number of stem cells, senescence resulting from “aging” genes, free 
radical damage, DNA damage, changes in telomere length and planned cell death have 
been proposed to explain the phenomenon of aging (Jin, 2010). Defining aging in a way 
classifies scientists, where some consider aging as a disease, whereas some consider it a 
natural process. Aging, either as an immanent process or a disease in disguise, has an 
effect on an individual’s immune system and concomitantly on vaccine efficacy. 
 Older adults are at a higher risk of influenza-related illnesses, with the highest 
hospitalizations and influenza-related morbidity in individuals greater than 65 years of 
age than any other age group (CDC: People 65 Years and Older & Influenza). The 
influenza vaccine has shown to elicit a low antibody response in aged individuals than 
young adults. One of the solutions to this issue is to increase the dose of the current 
vaccine formulations. The inactivated seasonal influenza vaccine is available as both high 
dose and adjuvanted vaccines and has shown to increase the antibody response and 
decrease the influenza-related illnesses in the aged individuals (CDC: People 65 Years 
and Older & Influenza). The high dose vaccine contains four times the amount of antigen 
as a regular influenza shot and the adjuvanted influenza vaccine, commercially available 




response. Simonsen L et al., in 2007 published data and a review of multiple influenza 
vaccine efficacy trials demonstrating a variation in influenza rates in the elderly, which 
are seen to be rising in synchrony with vaccination rates, majorly showcasing the lack of 
sufficient protection provided by the seasonal influenza vaccines in the elderly. Yao X et 
al. published the results of the Beeson project, comparing the immune response post 
influenza vaccination in frail and non-frail aged. Frailty, a critical geriatric syndrome, 
was shown to be associated with impairment of TIV vaccine-induced antibody response 
and an increase in post-vaccination influenza infection (Yao X et al., 2011).   
Potluri et al., in 2019, published data determining the immune response post-vaccination 
with the monovalent 2009 H1N1 vaccine in different human age groups. The serological 
data showed that the adult females (18-49 years old) had a higher HAI and neutralizing 
antibody seroconversion than adult males and the aged males and females (65+ years 
old), 21 days post-vaccination. Their murine influenza vaccination studies demonstrated 
that post-vaccination with inactivated A/Cal/09 H1N1 influenza vaccine, the adult female 
mice (2-3 months old) had a significantly higher total IgG, IgG2c and neutralizing 
antibody response than the adult male and aged female (16-17 months old) mice (Potluri 
et al., 2019), depicting not just an age difference but also a sex-specific age difference in 
vaccine-induced immune response, with aged females showing a significant decline in 
immunity and higher morbidity as compared to adult females.  
As mentioned earlier, the IIVs have their primary response towards the HA head region, 
whereas several of the UIV in development have an antibody response directed towards 
the HA stalk. Whether these universal influenza vaccines are also influenced by host 




study. To understand this, we focused on evaluating the impact biological sex and age has 
on chimeric hemagglutinin (cHA) based universal influenza vaccine-induced immunity in 


















MATERIALS AND METHODS 
Animals: 
Adult (8-10 weeks) and aged (68-70 weeks) male and female C57BL/6 mice were 
purchased from Charles River Laboratories or the National Institute on Aging, 
respectively. All animals were housed 5 per cage. The mice were housed under standard 
biosafety level (BSL) 2 conditions with a 14:10 light: dark cycle and food and water 
provided ad libitum. All animals were given 2-4 weeks to acclimate to the housing 
conditions of Johns Hopkins School of Public Health.  
Ethics statement:  
All animal procedures were approved by the Johns Hopkins University Animal Care and 
Use Committee (MO18H250). This research project utilized mice, which are essential 
because their immune responses to vaccines mimic those observed in humans. The 
animal testing for this research is irreplaceable because studying the impact of the 
vaccination requires studying immune responses in an in vivo model that cannot be 
evaluated through in vitro study. Only trained individuals certified by the Johns Hopkins 
University for Animal Care and Use were allowed to handle the animals. The animals 
were continuously under supervision and were maintained in a healthy environment. 
Cells and Viruses: 
Madin Darby Canine Kidney (MDCK) cells were obtained from the American Type 
Culture Collection (ATCC) and were maintained in Dulbecco's modified Eagle's medium 




100 units/ml of penicillin-100 μg/ml of streptomycin (Pen/Strep; Gibco). Dr. Florian 
Krammer, in Icahn School of Medicine at Mount Sinai, New York, USA, provided the 
live influenza B virus (B/Yamagata/16/1988 virus; 1.4 x 107 PFU/ml) expressing 
chimeric H9/1 HA protein, cH11/1 recombinant chimeric HA protein and cH12/1 
recombinant chimeric HA protein for mice vaccination. H9N2 virus protein (HA and NA 
from A/Chicken/Hong Kong/G9/1997, backbone from A/PR/8/1934), H6N3 virus protein 
(HA and NA from A/Swine/Missouri/4296424/2006, backbone from A/PR8/1934) and 
H5N1 virus protein (HA and NA from A/Vietnam/1204/2004, backbone from 
A/PR8/1934) for testing the cross-reactive serum anti-stalk IgG antibody responses. 
Mouse-adapted A/California/04/2009 H1N1virus generated by Dr. Andrew Pekosz, Johns 
Hopkins Bloomberg School of Public Health, was used for the challenge studies in mice.  
Vaccination and Infection: 
We utilized a cHA universal influenza vaccine regimen with prime-two boosts (LAIV-
IIV-IIV) strategy (Krammer et al., 2013). The first vaccination comprises of a live 
influenza B virus (B/Yamagata/16/1988 virus; 1.4 x 107 PFU/ml), containing a chimeric 
H9/1 HA protein, delivered intranasally (IN) at a dose of 2.0 x 105 PFU in 50μL PBS per 
mouse. The first vaccination primed the immune response to the HA stalk. The second 
vaccination, administered 3-weeks later comprised of 10 μg of cH11/1 recombinant 
chimeric HA protein and10μg of Poly I:C adjuvant in sterile phosphate buffer saline 
(PBS) that was administered IN and intra-muscularly (IM) at 5μg/dose in 50μL/route. 
The third vaccination administered 3-weeks later comprised of 10 μg cH12/1 
recombinant chimeric HA protein, 10μg of Poly I:C adjuvant and PBS administered IN 




collection via retro-orbital bleeding to obtain serum from the vaccinated and 
unvaccinated mice three weeks after the third vaccination. One week after the blood 
collection, mice were challenged IN with a mouse-adapted A/California/04/09 virus at a 
dose of 102  TCID50 in a volume of 30μL under ketamine-xylazine anesthesia 
(100mg/ml). Subsets of mice were either euthanized at 5 days post-challenge to collect 
lung tissue for viral titration or were monitored for two weeks for changes in body mass 
and body temperature. Mice below 30% of weight loss as compared to its weight on the 
day of infection were discontinued from the study and euthanized. 
Anti-Influenza HA stalks Enzyme-Linked Immunosorbent Assay (ELISA): 
Enzyme-linked immunosorbent assay (ELISA) plates (Flat bottom, Microlon 96-well 
high-binding plates manufactured by Greiner Bio-One) were coated with 100 ng of 
purified virus protein of mouse-adapted H1N1 or H3N2 (A/Hong Kong/1968); 250ng of 
H9N2 (HA and NA from A/Chicken/Hong Kong/G9/1997, backbone from 
A/PR/8/1934), H5N1(HA and NA from A/Vietnam/1204/2004, backbone from 
A/PR8/1934) or H6N3 (HA and NA from A/Swine/Missouri/4296424/2006, backbone 
from A/PR8/1934) viruses in a carbonate-bicarbonate buffer (pH 9.6) and incubated at 
4°C overnight. After washing with wash buffer (1x PBS + 0.1% Tween-20), the plates 
were blocked with 10% dry milk in wash buffer and incubated for 1hr at 37°C. The 
blocking buffer was removed, serially diluted serum was added, and plates were 
incubated at 37°C for 1hr. After washing three times with wash buffer, secondary 
antibody [IgG(1:250)/IgG1(1:6000)/IgG2c (1:20000) in Wash buffer; Sigma Aldrich] 
was added and incubated for 1hr at 37°C. The plates were washed three times with wash 




minutes. The reaction was stopped using 1N HCl. Absorbance was measured at 450nm 
using the ELISA plate reader. The endpoint titer is determined by calculating the cut-off 
value as three times the background absorbance. 
Anti-Influenza HA stalk Avidity ELISA: 
Enzyme-linked immunosorbent assay plates (Flat bottom, Microlon 96-well high-binding 
plates manufactured by Greiner Bio-One) were coated with 100 ng of purified 
A/California/04/09 H1N1 virus protein in a carbonate-bicarbonate buffer (pH 9.6) and 
incubated at 4°C overnight. After washing with wash buffer (1x PBS + 0.1% Tween-20), 
the plates were blocked with 10% dry milk in wash buffer and incubated for 1hr at 37°C. 
The blocking buffer was removed, serum was plated in quadruplets at 1:50 dilution (in 
wash buffer) and incubated for 1hr at 37°C. Ammonium thiocyanate (Sigma) at 1M 
concentration was added to the serum in duplicate, with control wells receiving wash 
buffer only. After 15 minutes, the samples were washed eight times with a wash buffer. 
IgG secondary antibody (1:250 in Wash buffer; Sigma Aldrich) was added and incubated 
for 1hr at 37°C. The plates were washed three times with wash buffer and reactions were 
developed with 3,3’,5,5’-tetramethylbenzidine (TMB) for 20 minutes. The reaction was 
stopped using 1N HCl. Absorbance was measured at 450nm using a plate reader and final 
ratios were obtained by dividing normalizing samples with ammonium thiocyanate to 
corresponding ones without it. 
Passive serum transfer experiment:  
Adult male and female (8-10 weeks old) C57BL6 mice were vaccinated with the 




2013). Serum was collected 21 days post third vaccination. Serum from adult mice of 
each sex was pooled and an ELISA was performed to evaluate the average serum IgG 
(1:250 in Wash buffer; Sigma Aldrich) titer before the passive transfer. Unvaccinated 
male and female aged (68-70 weeks old) mice were injected 300uL of serum or PBS, 
with male and female aged mice receiving male and female adult, vaccinated pooled 
serum, respectively. Mice were allowed to rest for 2 hours post serum transfer, blood was 
collected from the recipient mice and ELISA was performed to check the antibody titer 
post-transfer. Mice were then challenged with 102 TCID50 ma2009 H1N1 viruses and 
monitored for 14 days morbidity and mortality. 
TCID50 virus titration and quantification: 
Lungs were homogenized in a serum-free DMEM media using PowerGen 125 Fisher 
Scientific homogenizer. Lung homogenates were spun at 4000 rpm for 20 minutes. The 
supernatant from each sample was collected and stored at -80ºC. For virus titration, lung 
homogenates were 10-fold serially diluted in DMEM (serum-free) and transferred to the 
96 well cell-culture plates (Greiner Bio-one) containing confluent MDCK cells and 
incubated for 6 days at 32 oC followed by fixation with 4% formaldehyde solution and 
staining with naphthol blue-black solution. Virus titers were calculated using the TCID50 
calculator(REED & MUENCH, 1938). 
Hemagglutinin Inhibition Assay (HAI): 
Sample preparation: Mouse serum samples were heat-inactivated for 35 minutes at 56°C. 
Samples (25μl) were diluted with 25μl of 5% sodium citrate and 50μl sterile normal 




drop (50μl) of packed turkey red blood cells was added to the sample, mixed and 
incubated at 4°C for 30 minutes. Samples were centrifuged at 2000rpm for 10 minutes at 
4°C and supernatant was separated.  
Hemagglutination assay (HA): Hemagglutination assay (HA) was performed by serially 
diluting 25μl of the virus across a round-bottom 96 well plate in 25μl of 0.01M PBS. 50μl 
of 0.5% RBC suspension was added to the virus dilutions and the plate was sealed with a 
clear film and incubated at room temperature for 1 hour for HA reaction to develop. The 
HA titer was determined by the highest dilution causing complete agglutination.  
Hemagglutination inhibition assay (HAI): For the hemagglutination inhibition assay 
(HAI), mouse serum was serially diluted across the plate in PBS to obtain 1:10 dilution. 
To 25μl of serum, an equal amount (25μl) of 4 HA units of virus dilution was added per 
well and incubated at room temperature for 1 hour. 50μl of 0.5% RBC suspension was 
added and the plate was sealed and incubated at room temperature for 2 hours for the 
mixture to agglutinate. The HAI titer was calculated as the reciprocal of the highest 
dilution causing complete inhibition of agglutination. 
Statistical analyses:  
Antibody responses and virus titers were analyzed by two-way ANOVA with age and sex 
as comparing factors and comparisons were performed using the Tukey multiple 
comparison test. Morbidity data (% change in body weight) were analyzed with two-way 
ANOVA (Mixed effects model) with Geisser-Greenhouse correction and comparisons 
























Age differences, driven mainly by females, were observed in stalk-specific antibody 
responses to H1N1 virus after vaccination 
To explore the impact of biological sex and age on chimeric hemagglutinin (cHA)-based 
universal influenza vaccine immunity,  adult (8-10 weeks) and aged (68-70 weeks) male 
(dark or light blue, respectively) and female (dark or light pink, respectively) mice were 
vaccinated thrice with chimeric hemagglutinin (cHA)-based UIV at 3-weeks interval and 
serum samples were collected on day 63 (i.e. 21 days after 3rd vaccination) (Fig 3A). The 
HA chimera used in the vaccine formulation is based on the backbone of H1 stalk. 
Hence, the antibody responses were checked against the H1N1 virus. The measured 
ELISA antibodies are stalk specific as there is a mismatch between the head region of 
coating reagents (H1 head) and head region of the chimeras (H9, H11, H12) used for 
immunization. HAI assay was performed, and we observed no result in all the serum 
samples tested, reconfirming the antibody response was HA-stalk directed not towards 
the HA head (data not shown). Stalk-specific anti-2009 H1N1 IgG (Fig 3B; *p<0.05); 
anti-2009 H1N1 IgG2c (Fig 3C; *p<0.05); anti-2009 H1N1 IgG1 (Fig 3D) responses 
measured indicated that adult mice generated a significantly higher anti-stalk IgG and 
IgG2c antibody response than the aged mice, whereas the IgG1 response had no 
significant difference. The mean antibody titers were lower for anti-HA stalk IgG1 than 
IgG and IgG2c antibodies, indicating lower induction of IgG1 in C57BL6 mice post 




Moreover, the age-associated decline in antibody responses was mainly driven by 
females, observed with a significant difference in total IgG and IgG2c antibodies between 
adult females and aged females, characterized with a significant age-associated decline in 
females specifically (Fig 3B, C; *p<0.05), which has also been observed previously with 
the IIV (Potluri et al., 2019). Antibody responses between the sexes, however, were 
similar in adult as well as aged mice.  
To test if there is a difference in the avidity of the stalk specific antibodies between the 
cohorts’ immune response, we performed the anti-H1N1 specific IgG antibody avidity 
ELISA on serum collected at 63 days post-vaccination. Avidity gives a measure of the 
overall strength of an antibody-antigen complex. It is dependent on the affinity of the 
antibody for the epitope along with the valency of both the antibody and antigen (Pullen, 
Fitzgerald, & Hosking, 1986). We observed that the adult mice had a significantly higher 
avidity response than the aged mice, indicating that the antigen-antibody binding is better 
in adult mice as compared to the aged mice (Fig 3E; *p<0.05). Consistent with the total 
anti-stalk-specific IgG and IgG2c antibody responses, the age-related decline in antibody 
avidity was only observed among females, as we saw a significant difference in adult 
females and aged female mice (Fig 3E; *p<0.05). Overall, these results indicate that not 
just the quantity but also the quality of antibody response post-vaccination with the cHA 
based UIV is significantly better in adult mice as compared to the aged mice and there is 
a salient sex-dependent effect of aging observed in immunity, driven by the females.  
Antibody responses were analyzed by two-way ANOVA with age and sex as comparing 
factors and comparisons were performed using the Tukey multiple comparison test. Data 





Vaccination provided protection to both young and aged male and female mice as 
compared to their naïve counterparts after challenge. 
Challenge studies dictating the efficacy of the cHA based UIV were performed in 7-8 
weeks old females BALB/c mice. We wanted to expand on these results and test whether 
the protection stays consistent across different sex, age and strain of mice as compared to 
their unvaccinated counterparts. To test this, adult and aged mice, vaccinated or 
unvaccinated, were challenged with 102 TCID50 of ma2009 H1N1 influenza A virus 
delivered intranasally (Fig 4A). Vaccinated mice were challenged 70 days post-
vaccination and unvaccinated mice were age-matched with vaccinated mice during the 
challenge. One set of mice were euthanized at 5 days post-challenge to measure viral 
replication in the lungs and another set was monitored for 14 days post-challenge to 
evaluate morbidity (Fig 4A). Compared to unvaccinated mice, vaccinated mice had 
significantly lower virus replication in the lungs in males and females of the adult as well 
as the aged group. In adult mice, vaccinated male and female mice had significantly 
lower lung viral titers at 5 days post-challenge than their unvaccinated counterparts (Fig 
4B; *p<0.05). 
Similarly, in aged mice, vaccinated male and female mice were able to clear the virus 
better from the lungs, as evidenced by significantly lower viral titers than their 
unvaccinated counterparts (Fig 4D; *p<0.05). To evaluate morbidity, the percent change 
in body mass was measured daily for 14 days post-challenge, as a decline in body weight 
post-infection is one of the clinical symptoms exhibited in the mouse model. The 




morbidity than the vaccinated mice (Fig 4C, E; *p<0.05). Moreover, we confirmed the 
greater morbidity females experience as compared to the males after infection with the 
influenza virus, as evidenced by a significant difference in loss of body weight between 
unvaccinated females and unvaccinated males of both adult as well as aged mice (Fig 4C, 
E; *p<0.05). Comprehensively this indicated that vaccination protected mice of all sexes 
and ages better than the unvaccinated.  
We also compared virus clearance from lungs and morbidity between the vaccinated 
adult and aged mice. There was a significant difference observed between the lung viral 
clearance between adult mice and aged mice (Fig 5A; *p < 0.05). The aged females had 
significantly higher lung viral titers than its adult counterpart, along with having the 
highest viral titers overall amongst all the cohorts (Fig 5A). Morbidity comparison 
between the four groups revealed that the aged females suffered the most morbidity, aged 
males experienced intermediate bodyweight loss and adult male and female mice had 
comparable morbidity (Fig 5B). Both the lung viral titers and morbidity studies 
correspond with the antibody data (Fig 3 B, C, D) in terms of demonstrating age-
associated sex differences, where the vaccinated aged females had lowest antibody titers 
compared to the other vaccinated groups. These results overall suggest that vaccinated 
mice are better protected than unvaccinated mice. Meanwhile, amongst vaccinated, the 
vaccine-induced response is lowest amongst aged females and correspond in terms of 
protection with providing insufficient protection as compared to vaccinated aged males 
and adult mice.  
Virus titers were analyzed by two-way ANOVA with age and sex as comparing factors 




data (% change in body weight) were analyzed with two-way ANOVA (Mixed effects 
model) with Geisser-Greenhouse correction and comparisons were performed using the 
Tukey multiple comparison test. Data was considered statistically significant at p<0.05 
 
Female-biased effect of aging in antibody response is conserved across different 
subtypes of group 1 viruses but not group 2 influenza A viruses 
Characterizing the universal nature of the stalk specific antibodies, Krammer et al. 
demonstrated that vaccination in adult female BALB/c mice and adult female fitch ferrets 
with the chimeric hemagglutinin (cHA)-based UIV offered protection against challenge 
with multiple group 1 influenza viruses including H5N1, H1N1, and H6N1 viruses 
(Krammer et al., 2013). To evaluate if host factors impact this cross-protection across 
multiple influenza subtypes, we vaccinated adult and aged mice three times at a 3-weeks 
interval with chimeric hemagglutinin (cHA)-based UIV and serum samples were 
collected 21 days post 3rd vaccination (Fig 3A). Serum IgG antibody response against 
H9N2 virus (HA and NA from A/Chicken/Hong Kong/G9/1997, backbone from 
A/PR/8/1934) (Fig 6A); H6N3 virus (HA and NA from 
A/Swine/Missouri/4296424/2006, backbone from A/PR8/1934) (Fig 6B); H5N1 virus 
(HA and NA from A/Vietnam/1204/2004, backbone from A/PR8/1934) (Fig 6C); and 
H3N2 virus (A/Hong Kong/1968) (Fig 6D) was evaluated in serum. The age-associated 
female bias was conserved across multiple group 1 influenza viruses, specifically H9N2 
and H6N3. Total IgG response against H9N2 revealed a similar trend as observed with 
against H1N1 virus (Fig 3B), where adult mice generated a significantly greater antibody 




other groups (Fig 6A; *p < 0.05). Similar responses were recorded against the H6N3 
virus (Fig 6B; *p < 0.05). There were no significant sex or age differences in response to 
the H5N1 virus in the serum. However, aged females still had the lowest average IgG 
antibody titer (Adult males=703; Adult females=523; Aged males=286; Aged 
females=123) than other groups (Fig 6C). There was a minimum or undetectable 
response to the H3N2 virus (Fig 6D), a Group 2 influenza virus, which reconfirms the 
results previously observed in mice studies (Krammer et al., 2013). Taken together, this 
data suggests that even the cross-reactive nature of the antibody response demonstrates 
differential response amongst the age groups and continues to decline significantly more 
in females.  
Antibody responses were analyzed by two-way ANOVA with age and sex as comparing 
factors and comparisons were performed using the Tukey multiple comparison test. Data 
was considered statistically significant at p<0.05 
Passive serum transfer of stalk specific antibodies from vaccinated adult mice does 
not protect against morbidity in sex-matched aged mice 
Restating the results previously observed where the adult mice induced significantly 
higher antibody response than the aged mice, we wanted to test whether transferring these 
stalk specific antibodies produced in vaccinated adult mice would be protective in aged 
mice. We collected blood from adult male (Dark blue; solid) and female mice (Dark pink; 
solid) at 63 days post-primary vaccination with the chimeric hemagglutinin (cHA)-based 
UIV and tested the pooled serum for total IgG titers from both males and females. Both 
adult male and females had an equivalent endpoint titer of 6400 (Data not shown). Either 




counterparts (light blue or pink; Open) (Fig 7A). After 2 hours of serum transfer, blood 
was collected again, and serum was tested to ensure successful serum transfer prior to 
challenge (Data not shown). Challenge with 102 TCID50 of ma2009 H1N1 virus 
demonstrated that the aged males, as well as females receiving serum from adult females, 
suffered morbidity evidenced through the loss of body weight in the mice (Fig 7B, C). 
The passive serum recipient aged females, however, lost more body weight as compared 
to the serum recipient aged males. When compared with the vaccinated aged male and 
female mice, the passive serum recipient mice lost more body weight (Fig 7B, C). A 
transfer of serum from vaccinated adult females into naïve adult female mice has shown 
to confer protection from multiple group 1 viruses, whereas this passive transfer of 
antibodies is not enough to protect the aged mice sufficiently, and observed protection 
still is worse in females than males. This data overall indicates that there are underlying 
fundamental mechanisms of aging that exist differentially between the sexes and drive 
female-biased effects in aging.  
Morbidity data (% change in body weight) were analyzed with two-way ANOVA (Mixed 
effects model) with Geisser-Greenhouse correction and comparisons were performed 


















































































































































































Figure 4: Lung viral titers and morbidity measure in vaccinated and unvaccinated 






























































































































Figure 5: Comparison of lung viral titers and morbidity measure between adult and 
aged vaccinated mice post-challenge with the H1N1 virus 
 





























































































Figure 6: Heterosubtypic immune response post-vaccination with the chimeric 








































































































































Figure 7: Comparison between protection conferred by the vaccine and passively 
transferred stalk-specific antibodies in aged mice  
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Influenza causes approximately 9 to 45 million illnesses and 12,000 to 61,000 
deaths annually in the past decade in the United States alone (CDC: Disease Burden of 
Influenza). A 2018 study estimated the average annual economic burden of influenza to 
be around $11.2 billion (Putri, Muscatello, Stockwell, & Newall, 2018) in the United 
States. Moreover, seasonal influenza vaccines, which are the best line of defense against 
influenza transmission and infection, are still not optimized. Seasonal influenza vaccine 
manufacture requires annual update via rigorous surveillance and often results in limited 
vaccination coverage (Houser and Subbarao, 2015). The seasonal IIVs still produce a 
substantial health benefit in terms of the number of cases averting illnesses, 
hospitalizations, and clinic visits (Kostova et al., 2013). However, the vaccine efficacy 
varies vastly between different ages of the vaccinees each year and is affected by several 
viral as well as host factors (Dhakal & Klein, 2019) (Harding & Heaton, 2018) (States et 
al., 2020).  
With the limitations observed with the seasonal influenza vaccines and 
advancement in influenza vaccine research, multiple platforms are coming into the 
picture. In terms of providing broader protection, pan-subtype, pan-group/multi-lineage 
and universal influenza vaccines are the key players in influenza vaccine research (Y. H. 
Jang & Seong, 2019). UIVs targeting the stalk region of the hemagglutinin (HA) protein, 
including the headless HA model, chimeric HA model, mosaic HA model and virus-like 
particles (VLP) expressing HA stalk domain are prospective platforms that can 
eventually enter commercialization. Recognizing the impact of host factors on seasonal 




biological sex and age in the context of universal influenza vaccine (stalk specific) 
induced responses in mice models.  
We focused on the cHA based UIV, which has been shown to protect female 
BALB/c mice and ferrets against challenge with multiple group 1 influenza viruses 
(Krammer & Palese, 2013). Humoral immunity is the critical mechanism of the 
protection conferred by the cHA-based universal influenza vaccination (Krammer et al., 
2013). Hence antibody analysis is essential in our study to determine the quality and 
extent of protection provided by this vaccine regimen.  
Although the HAI assay has been the gold standard as a relative measure of  
protection for head-specific antibody response, the cHA-based UIV induces a stalk-based 
response, which is non-neutralizing and hence cannot be detected by HAI assay (data not 
shown). The IgG antibody is a significant component of humoral immunity and is 
involved heavily in the ADCC mechanism during viral infection (Teillaud, 2012). In our 
study, the HA stalk-specific total IgG antibody response was observed to be significantly 
higher in the adult mice as compared to the aged mice against influenza A H1N1 virus. 
Moreover, this age difference was sex-specific, with aged females having a greater 
reduction in immune responses than the aged males. The age-associated decline in 
females was observed with total IgG2c antibodies as well. However, there was no 
significant difference in the IgG1 antibody response. A similar trend in IgG isotype 
response was observed post-vaccination with IIV in mice (Potluri et al., 2019). Our 
results align with the prior research demonstrating that the IgG2a/c antibody is the 
predominant immunoglobulin isotype in most viral infections in mice (Raval et al., 




Our study also highlights the cross-reactive nature of the stalk specific antibodies 
through a sex and age perspective. Adult mice exhibited significantly higher IgG titers 
against the H9N2 and H6N3 viruses as compared to aged mice, meanwhile, aged females 
demonstrated the lowest titers. No significant difference was observed in IgG response to 
the H5N1 virus and the overall titers were lower than those induced in response to other 
group 1 viruses. There was minimum detection of IgG response against the H3N2 virus, a 
group 2 influenza virus. Thus, our results suggest that this cHA based UIV platform 
creates a heterosubtypic response only against group 1 influenza viruses. A similar cHA 
based UIV based on the backbone of H3 stalk protects mice against group 2 influenza 
viruses. Perhaps, combining formulations of both aforementioned regimens could provide 
us with an improved UIV platform. The stalk-based antibody avidity is observed to be 
superior to the head-specific antibody response following pandemic H1N1 vaccination 
(Tete et al., 2016). The stalk specific antibody avidity, however, has not been evaluated 
between different age groups and sexes. We found the quality of antibody response to be 
higher in adult mice as compared to the aged mice, indicating an overall superior 
antibody response in adult mice. 
Vaccination with a cHA-based universal influenza vaccine protects adult female 
BALB/c mice better than unvaccinated mice (Krammer et al., 2013). We confirmed this 
result in adult and aged, male and female C57BL6 mice using a sublethal dose of H1N1 
influenza virus. Amongst vaccinated groups, challenge with H1N1 virus resulted in the 
highest morbidity in aged females, evidenced by the increased loss in body weight and 
higher viral replication in lungs, compared to other groups. Dendritic cells have shown to 




could also be one of the reasons why there is insufficient protection in aged mice as this 
vaccine platform utilizes a Poly(I:C) adjuvant, a TLR3 stimulant. Future analysis using a 
higher dose of the Poly(I:C) adjuvant in aged mice can confirm this speculation.  
There was no significant sex difference in immunity and protection in adult mice. 
Women show higher antibody responses, almost two-fold than men, following a full dose 
of TIV (Engler et al., 2008). Vaccination with IIV in mice models has demonstrated a sex 
difference in IgG, IgG2c and neutralizing antibody responses between males and females. 
Escape in X chromosome inactivation leading to a greater expression of toll-like receptor 
7 (Tlr7) in B cells of females is associated with a higher antibody response post-
vaccination with the IIV, than their adult male counterparts  (Fink et al., 2018). The 
impact of sex hormones and genetic factors have not been explored in the context of 
stalk-based responses and can be crucial in understanding the sex-specific differences, or 
lack thereof, in adults following this vaccine regimen. Whether the introduction of a 
TLR7 agonist adjuvant such as Imiquimod in the vaccine formulation of this regimen can 
induce a differential immune response between the sexes can be potentially explored in 
the future.  
Passive serum transfer of stalk specific antibodies from vaccinated young adult 
female mice resulted in protection in adult female mice (Krammer et al., 2013). Whether 
this protection persists across ages is also unknown. Passive serum transfer to aged mice 
did not significantly decrease morbidity in either males or females. Vaccinated aged mice 
exhibited a lower decline in body weight, compared to the passive serum recipients. As 
mentioned earlier, this could be due to a lack of induction of TLR3 pathway by Poly(I:C) 




serum from adult females suffered higher morbidity compared to their male counterparts, 
despite similar IgG antibody titers in the donor serum of males and females. Again, this 
reiterates the presence of a sex-based decline in immunity post-vaccination or infection 
and suggests the presence of fundamentally distinct mechanisms of aging between males 
and females.   
Aging, as a phenomenon, is often assumed to be the same in both the sexes. 
However, lifespan, age-related diseases, infection susceptibility, human peripheral blood 
mononuclear cell (PBMC) analysis and our data indicate otherwise (Márquez et al., 
2020). There is a sexual dimorphism observed in the life expectancy of humans where 
females are exceeding men, a phenomenon also observed in other mammalian species, 
including laboratory rats (Sampathkumar et al., 2020)(Clutton-Brock & Isvaran, 2007). 
Characterization of PBMCs in the human population of varying ages revealed an 
epigenomic indication of declining B cell loci, T cell population and increasing monocyte 
and cytotoxic cell functions at a higher magnitude in males (Márquez et al., 2020). 
Additionally, age-associated depletion of sex hormones (testosterone in men and estrogen 
and progesterone in women) has been linked to dysregulation of the immune system 
(Gubbels Bupp et al., 2018). Specific to influenza vaccination responses in humans, 
females have been linked with having a stimulatory effect of estrogen and males with a 
suppressive effect of testosterone on vaccine-induced antibody responses. It is evidenced 
with females of reproductive age having high neutralizing antibody seroconversion than 
aged females, post-vaccination with the IIV (Potluri et al., 2019), which also aligns with 




context of universal influenza vaccines may help us get a better idea about the interplay 
between the HA-stalk specific response and the host factors.  
The mechanism of action for cHA-based UIVs is the production of stalk-specific 
antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) (Krammer & 
Palese, 2013). Whether there are differences in ADCC response post-vaccination is still 
under investigation. In case of measles, lower sex-specific survival rates have been linked 
to decreased ADCC activity in adult females, post-infection and vaccination, than males 
(Atabani et al., 2000). Along similar lines, HIV infected men have shown to generate 
higher ADCC levels than females (Nag et al., 2004). Hence, more research towards 
influenza specific ADCC response is crucial in understanding the differences observed in 
immunity.  
Another universal influenza vaccine candidate, utilizing a recombinant adenovirus 
expressing influenza A nucleoprotein (A/NP) and matrix 2 (M2) (A/NP + M2-rAd), 
revealed a decline in antigen-specific systemic antibody and T cell responses (García et 
al., 2016). The phase 1 clinical trial interim results of the chimeric HA-based UIV 
regimens with an adjuvanted chimeric haemagglutinin-based IIV demonstrated high 
serum IgG stalk-reactive antibody titers protective against all group 1 haemagglutinin-
expressing viruses and no safety concerns post-vaccination (Bernstein et al., 2020). With 
the phase 1 clinical trial showing promising results, it is an excellent opportunity to take 
advantage of prior research done on host factors and explore their roles in vaccine before 
it enters the next step of production. 
Aged individuals currently makeup around 962 million in the global population 




population and economic dynamics globally (United Nations: World Population Ageing, 
2017). They remain a high-risk population for various viral infections, including the 
current ongoing CoVid19 pandemic (CDC: Coronavirus Diseases 2020). With the 
dramatic differences observed in the immune response to influenza vaccination and 
infection in different ages and sexes of the population, it is vital to examine these factors 
for any upcoming candidate vaccine for their ability to protect different demographics 


















• Figure 3: Anti H1N1 stalk specific antibody response in vaccinated mice  
Adult (8-10 weeks) and aged (68-70 weeks) male (dark or light blue, respectively) and 
female (dark or light pink, respectively) mice were vaccinated thrice with chimeric 
hemagglutinin (cHA)-based universal influenza vaccine at 3-weeks interval and serum 
samples were collected on day 63 (i.e. 21 days after 3rd vaccination) (A). Stalk-
specific anti-2009 H1N1 IgG (B); anti-2009 H1N1 IgG2c (C); anti-2009 H1N1 IgG1 
(D); and anti-2009 IgG antibody avidity (E) responses were measured in serum. LOD 
represents limit of detection. Data represent mean ± standard error of the mean from 
two or three independent replications (n = 11-45/group) and significant differences 
between groups are denoted by asterisks (*p<0.05) based on two-way ANOVAs. 
 
• Figure 4: Lung viral titers and morbidity measured in vaccinated and 
unvaccinated mice post-challenge with the mouse-adapted 2009 H1N1 virus 
Adult (8-10 weeks) and aged (68-70 weeks) male (dark or light blue, respectively) and 
female (dark or light pink, respectively) mice were either unvaccinated or vaccinated 
thrice with chimeric hemagglutinin (cHA)-based universal influenza vaccine at 3-
weeks interval, serum samples were collected on day 63 and mice were challenged 
with 102 TCID50 of ma2009 H1N1 influenza A virus at day 70 (A). To evaluate 
morbidity, the percent change in body mass were measured daily for 14 days post 
challenge in adults (B) and aged (D) mice (n = 5-10/group). Lung virus titers were 
measured on day 5 post challenge (n = 4-10/group) in adult (C) and aged (E) mice. 




from two independent replications (n = 4-10/group) and significant differences 
between groups are denoted by asterisks (*p<0.05) based on repeated measures 
ANOVA for morbidity data and unpaired T-test for virus titer. 
• Figure 5: Comparison of lung viral titers and morbidity in adult and aged 
vaccinated mice post-challenge with the H1N1 virus 
Adult (8-10 weeks) and aged (68-70 weeks) male (dark or light blue, respectively) and 
female (dark or light pink, respectively) mice were vaccinated thrice with chimeric 
hemagglutinin (cHA)-based universal influenza vaccine at 3-weeks interval, serum 
samples were collected on day 63 and mice were challenged with 102 TCID50 of 
ma2009 H1N1 influenza A virus on day 70 (A). To evaluate morbidity, the percent 
change in body mass was measured daily for 14 days post challenge (B). Lung virus 
titers were measured on day 5 post challenge (n = 6-10/group) (C). Data represent 
mean ± standard error of the mean from two independent replications (n = 4-10/group) 
and significant differences between groups are denoted by asterisks (*p < 0.05) based 
on repeated measures ANOVA for morbidity data and two-way ANOVA for virus 
titer. 
• Figure 6: Heterosubtypic immune responses post-vaccination with the chimeric 
hemagglutinin (cHA) based universal influenza vaccine 
Adult (8-10 weeks) and aged (68-70 weeks) male (dark or light blue, respectively) and 
female (dark or light pink, respectively) mice were vaccinated thrice with chimeric 
hemagglutinin (cHA)-based universal influenza vaccine at 3-weeks interval and serum 
samples were collected on day 63 (i.e. 21 days after 3rd vaccination). Stalk-specific 




Kong/G9/1997, backbone from A/PR/8/1934); (B) H6N3 virus (HA and NA from 
A/Swine/Missouri/4296424/2006, backbone from A/PR8/1934); (C) H5N1 virus (HA 
and NA from A/Vietnam/1204/2004, backbone from A/PR8/1934) and (D) H3N2 
virus (A/Hong Kong/1968). LOD represents limit of detection. Data represent mean ± 
standard error of the mean from two independent replications (n=11-15/group) and 
significant differences between groups are denoted by asterisks (*p<0.05) based on 
two-way ANOVA. 
• Figure 7: Comparison between protection conferred by the vaccine and passively 
transferred stalk-specific antibodies in aged mice 
Aged (68-70 weeks) vaccinated and unvaccinated males (Solid or Open light blue, 
respectively) and female (Solid or Open light pink, respectively) are age matched prior 
to the experiment. Unvaccinated male receive serum from adult vaccinated mice (not 
denoted) and unvaccinated female mice receive serum from adult unvaccinated mice 
(not denoted). Blood is collected following passive transfer of serum from the sexes. 
Both vaccinated and unvaccinated mice are challenged with 102 TCID50 of ma2009 
H1N1 influenza A virus (A). To evaluate morbidity, the percent change in body mass 
was measured daily for 14 days post challenge (B). Data represent mean ± standard 
error of the mean from one experiment (n = 5-10/group) and significant differences 
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